Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
January 13, 2020 08:18 ET
|
Resverlogix Corp
CALGARY, Alberta, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) is pleased to announce today additional highly significant findings and clear...
Resverlogix Appoints Dicky To to its Board of Directors
December 20, 2019 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announced that Mr. Dicky To has been appointed to the Company’s Board of...
Resverlogix Announces Change to its Board of Directors
December 11, 2019 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announced that Dr. Eldon Smith has stepped down from the Board of Directors,...
Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019
December 05, 2019 18:00 ET
|
Resverlogix Corp
CALGARY, Alberta, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) reminds stakeholders that the Company will hold a conference call and webcast on...
Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
December 02, 2019 08:30 ET
|
Resverlogix Corp
Apabetalone treatment improves cognition in CVD patients with diabetes Subsequent conference call & webcast scheduled to present BETonMACE prespecified cognition assessment results CALGARY,...
Resverlogix Announces Warrant Exercise Incentive Program
November 25, 2019 18:00 ET
|
Resverlogix Corp
CALGARY, Alberta, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) announces a warrant exercise incentive program (“Incentive Program”) designed to...
Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019
November 12, 2019 09:00 ET
|
Resverlogix Corp
CALGARY, Alberta, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has scheduled a conference call and webcast to supplement...
Resverlogix Announces Voting Results from the 2019 Annual Meeting of Shareholders
October 31, 2019 19:39 ET
|
Resverlogix Corp
CALGARY, Alberta, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary,...
Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
September 30, 2019 07:30 ET
|
Resverlogix Corp
BETonMACE did not meet the primary endpoint Apabetalone development to continue to be advanced by the Company based on BETonMACE resultsPrimary results to be presented during a late-breaking science...
Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
September 27, 2019 09:27 ET
|
Resverlogix Corp
CALGARY, Alberta, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has issued a 10% secured convertible debenture in the...